Annals of Surgical Oncology

, Volume 25, Issue 13, pp 4020–4026 | Cite as

Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer

  • Marta Sandini
  • Katarina J. Ruscic
  • Cristina R. Ferrone
  • Andrew L. Warshaw
  • Motaz Qadan
  • Matthias Eikermann
  • Keith D. Lillemoe
  • Carlos Fernández-del CastilloEmail author
Pancreatic Tumors



Dexamethasone is administered intraoperatively to prevent anesthesia-related nausea and vomiting and to reduce postoperative opioid administration. However, the adverse effects of corticosteroids on anastomotic healing and wound infection as well as oncologic outcomes remain unclear. We analyzed the effect of intraoperative dexamethasone administration on surgical outcomes after pancreaticoduodenectomy and on long-term survival in pancreatic cancer patients.


A total of 679 pancreaticoduodenectomies from a prospectively maintained database were analyzed. Surgical outcomes were compared between patients who received intraoperative dexamethasone and those who did not. Kaplan–Meier curves and Cox-regression survival analysis were performed in patients with pancreatic cancer. A propensity analysis was done to reduce the inherent bias of retrospective design.


Patients who received dexamethasone (117, 17.2%) were younger and more likely to be female than those who did not (p = 0.001). Overall and 30-day major morbidity were similar among all resected patients, although there were fewer infectious complications in the dexamethasone group (18.8% vs. 28.5%, p = 0.032). In pancreatic cancer patients, dexamethasone was associated with significantly improved median overall survival (46 vs. 22 months, p = 0.017). This effect occurred independently of stage, pathologic characteristics, or adjuvant therapy, with adjusted hazard ratios, derived from pre-propensity and post-propensity analysis, of 0.67 (0.47–0.97) and 0.57 (0.37–0.87), respectively.


A single intraoperative dose of dexamethasone did not increase morbidity after pancreaticoduodenectomy and, in fact, was associated with a decrease in infectious complications. The treatment was independently associated with improved overall survival in patients with pancreatic adenocarcinoma, an effect that cannot be explained and needs further validation in a prospective setting.


Conflict of interest

All the authors state that there is no conflict of interest.

Supplementary material

10434_2018_6827_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 17 kb)
10434_2018_6827_MOESM2_ESM.pdf (32 kb)
Supplementary material 2 (PDF 31 kb)


  1. 1.
    Lassen K, Coolsen MM, Slim K et al; ERAS® Society; European Society for Clinical Nutrition and Metabolism; International Association for Surgical Metabolism and Nutrition. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr. 2012;31(6):817–30.CrossRefGoogle Scholar
  2. 2.
    Xiong J, Szatmary P, Huang W et al. Enhanced recovery after surgery program in patients undergoing pancreaticoduodenectomy: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016;95(18):e3497.CrossRefGoogle Scholar
  3. 3.
    Braga M, Pecorelli N, Ariotti R et al. Enhanced recovery after surgery pathway in patients undergoing pancreaticoduodenectomy. World J Surg. 2014;38(11):2960–6.CrossRefGoogle Scholar
  4. 4.
    De Oliveira GS Jr, Castro-Alves LJ, Ahmad S, et al. Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials. Anesth Analg. 2013;116(1):58–74.CrossRefGoogle Scholar
  5. 5.
    Waldron NH, Jones CA, Gan TJ, et al. Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis. Br J Anaesth. 2013;110(2):191–200.CrossRefGoogle Scholar
  6. 6.
    Kleif J, Kirkegaard A, Vilandt J, et al. Randomized clinical trial of preoperative dexamethasone on postoperative nausea and vomiting after laparoscopy for suspected appendicitis. Br J Surg. 2017;104(4):384–92.CrossRefGoogle Scholar
  7. 7.
    Laaninen M, Sand J, Nordback I, et al. Perioperative hydrocortisone reduces major complications after pancreaticoduodenectomy: a randomized controlled trial. Ann Surg. 2016;264(5):696–702.CrossRefGoogle Scholar
  8. 8.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefGoogle Scholar
  9. 9.
    Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91.CrossRefGoogle Scholar
  10. 10.
    Klein Klouwenberg PM, Ong DS, Bonten MJ, Cremer OL. Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria. Intensive Care Med. 2012;38(5):811–9.CrossRefGoogle Scholar
  11. 11.
    Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):253–9.CrossRefGoogle Scholar
  12. 12.
    Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–8.CrossRefGoogle Scholar
  13. 13.
    Aasboe V, Raeder JC, Groegaard B. Betamethasone reduces postoperative pain and nausea after ambulatory surgery. Anesth Analg. 1998;87(2):319–23.PubMedGoogle Scholar
  14. 14.
    Doleman B, Sutton AJ, Sherwin M, et al. Baseline morphine consumption may explain between-study heterogeneity in meta-analyses of adjuvant analgesics and improve precision and accuracy of effect estimates. Anesth Analg. 2017;126(2):648–60.CrossRefGoogle Scholar
  15. 15.
    Kwon S, Thompson R, Dellinger P, et al. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. Ann Surg. 2013;257(1):8–14.CrossRefGoogle Scholar
  16. 16.
    Eriksen TF, Lassen CB, Gögenur I. Treatment with corticosteroids and the risk of anastomotic leakage following lower gastrointestinal surgery: a literature survey. Colorectal Dis. 2014;16(5):O154–60.CrossRefGoogle Scholar
  17. 17.
    Bartlett R, Hartle AJ. Routine use of dexamethasone for postoperative nausea and vomiting: the case against. Anaesthesia. 2013;68(9):892–6.CrossRefGoogle Scholar
  18. 18.
    McSorley ST, Roxburgh CSD, Horgan PG, McMillan DC. The impact of preoperative dexamethasone on the magnitude of the postoperative systemic inflammatory response and complications following surgery for colorectal cancer. Ann Surg Oncol. 2017;24(8):2104–12. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Toner AJ, Ganeshanathan V, Chan MT, et al. Safety of perioperative glucocorticoids in elective noncardiac surgery: a systematic review and meta-analysis. Anesthesiology. 2017;126(2):234–48.CrossRefGoogle Scholar
  20. 20.
    Singh PP, Lemanu DP, Taylor MH, et al. Association between preoperative glucocorticoids and long-term survival and cancer recurrence after colectomy: follow-up analysis of a previous randomized controlled trial. Br J Anaesth. 2014;113 Suppl 1:i68–73.CrossRefGoogle Scholar
  21. 21.
    Cata JP, Jones J, Sepesi B, et al. Lack of association between dexamethasone and long-term survival after non-small cell lung cancer surgery. J Cardiothorac Vasc Anesth. 2016;30(4):930–5.CrossRefGoogle Scholar
  22. 22.
    De Oliveira GS Jr, McCarthy R, Turan A, et al. Is dexamethasone associated with recurrence of ovarian cancer? Anesth Analg. 2014;118(6):1213–8.CrossRefGoogle Scholar
  23. 23.
    Call TR, Pace NL, Thorup DB, et al. Factors associated with improved survival after resection of pancreatic adenocarcinoma: a multivariable model. Anesthesiology. 2015;122(2):317–24.CrossRefGoogle Scholar
  24. 24.
    Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–61.CrossRefGoogle Scholar
  25. 25.
    Kim JH, Hwang YJ, Han SH, et al. Dexamethasone inhibits hypoxia-induced epithelial–mesenchymal transition in colon cancer. World J Gastroenterol. 2015;21(34):9887–99.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Marta Sandini
    • 1
  • Katarina J. Ruscic
    • 2
  • Cristina R. Ferrone
    • 1
  • Andrew L. Warshaw
    • 1
  • Motaz Qadan
    • 1
  • Matthias Eikermann
    • 2
  • Keith D. Lillemoe
    • 1
  • Carlos Fernández-del Castillo
    • 1
    Email author
  1. 1.Department of Surgery, Harvard Medical SchoolMassachusetts General HospitalBostonUSA
  2. 2.Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical SchoolMassachusetts General HospitalBostonUSA

Personalised recommendations